glp-1 receptor agonist drug list Comparing Ozempic, Wegovy and Other Drugs List of GLP-1 Receptor Agonists

While individual patients may report various symptoms while taking these medications, there is no official link between GLP-1 therapy and nocturnal hyperhidrosis (excessive nighttime sweating)

Furthermore, AMPK inhibitor compound C abolished the metformin-mediated upregulation of GLP-1R level and PKA phosphorylation

Two other pharmaceutical companies have their own oral GLP-1 drugs in the works: Orforglipron: Developed by Eli Lilly, its in Phase 3 clinical trials for treating type 2 diabetes and obesity, with an expected September 2025 completion

These barriers account to varying degrees for the reduced level of adherence described for multiple asymptomatic chronic conditions, including diabetes

GI adverse events are usually mild or moderate, dose-dependent, decline with continued treatment and do not affect glycaemic control